As the healthcare system adjusts to the transition to value-based care, providers in particular are having a hard time keeping up with all of the changes, said Andrei Gonzales, director of value-based reimbursement initiatives at McKesson Health Solutions.
As the healthcare system adjusts to the transition to value-based care, providers in particular are having a hard time keeping up with all of the changes, said Andrei Gonzales, director of value-based reimbursement initiatives at McKesson Health Solutions.
Transcript (slightly modified)
What remains the biggest hurdle facing the US in the move to value-based care?
I’d say the biggest hurdle is the transition from the current fee-for-service structure, to a value-based reimbursement structure. The study that we did shows that providers are struggling, and they are lagging payers in their progression towards value-based reimbursement.
And you know, providers have a very busy job right now just to take care of their patients, and the transition requires a lot of work in terms of building care coordination capabilities, in terms of building data integration so that all the different stakeholders in the continuum of care really understand what’s happening for their patients in these value-based models and understand where opportunities for improvement are, and to be able to make those changes to really see the improvements that they’re looking for. So that transition is going to be a very heavy lift; it has been and it’s going to continue to be until we reach more of a steady state and gone through this transition phase.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Bustling Gene Therapy Pipeline for Neuromuscular Diseases Brings Thorny Questions to the Clinic
March 18th 2025The rapid development of gene therapy options for treating neuromuscular diseases has created new therapeutic options but also logistical hurdles and a need for complex discussions between clinicians and families.
Read More